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CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at
relapse of childhood precursor-B–ALL provides improved strategies for selection
of stable PCR targets for monitoring of minimal residual disease
Tomasz Szczepan´ski, Marja J. Willemse, Bas Brinkhof, Elisabeth R. van Wering, Mirjam van der Burg, and Jacques J. M. van Dongen
Immunoglobulin (Ig) and T-cell receptor
(TCR) gene rearrangements are excellent
patient-specific polymerase chain reac-
tion (PCR) targets for detection of mini-
mal residual disease (MRD) in acute lym-
phoblastic leukemia (ALL), but they might
be unstable during the disease course.
Therefore, we performed detailed molecu-
lar studies in 96 childhood precursor-B–
ALL at diagnosis and at relapse (n 5 91)
or at presumably secondary acute my-
eloid leukemia (n 5 5). Clonal Ig and TCR
targets for MRD detection were identified
in 94 patients, with 71% of these targets
being preserved at relapse. The best sta-
bility was found for IGK-Kde rearrange-
ments (90%), followed by TCRG (75%),
IGH (64%), and incomplete TCRD rear-
rangements (63%). Combined Southern
blot and PCR data for IGH, IGK-Kde, and
TCRD genes showed significant differ-
ences in stability at relapse between
monoclonal and oligoclonal rearrange-
ments: 89% versus 40%, respectively. In
38% of patients all MRD-PCR targets were
preserved at relapse, and in 40% most of
the targets (> 50%) were preserved. In
22% of patients most targets (10 cases) or
all targets (10 cases) were lost at relapse.
The latter 10 cases included 4 patients
with secondary acute myeloid leukemia
with germline Ig/TCR genes. In 5 other
patients additional analyses proved the
clonal relationship between both disease
stages. Finally, in 1 patient all Ig/TCR
gene rearrangements were completely dif-
ferent between diagnosis and relapse,
which is suggestive of secondary ALL.
Based on the presented data, we propose
stepwise strategies for selection of stable
PCR targets for MRD monitoring, which
should enable successful detection of
relapse in most (95%) of childhood precur-
sor-B–ALL. (Blood. 2002;99:2315-2323)
© 2002 by The American Society of Hematology
Introduction
Several large prospective studies have clearly demonstrated the
high prognostic value of minimal residual disease (MRD) monitor-
ing in childhood acute lymphoblastic leukemia (ALL).1-4 Based on
the sensitive measurement of early response to cytotoxic treatment,
it is currently possible to identify not only patients at high risk for
relapse but also a group of low-risk patients with an excellent
relapse-free survival of more than 95%.4 Hence, MRD information
provides a new definition of remission in childhood ALL, which
justifies incorporation of MRD data in current treatment protocols
to refine risk assignment.5
Most MRD studies in pediatric precursor-B–ALL applied
immunoglobulin (Ig) and/or T-cell receptor (TCR) gene rearrange-
ments as polymerase chain reaction (PCR) targets for MRD
detection. They can easily be identified in most patients at
diagnosis with limited sets of PCR primers.6,7 Moreover, using
these molecular targets, sensitivities of 1024 to 1026 (1 malignant
cell within 104 to 106 normal cells) can be obtained routinely.7 With
the advent of novel real-time quantitative (RQ) PCR techniques,
Ig/TCR-based MRD techniques are now also quantitative.8-11
However, it is also known that Ig and TCR gene rearrangements
might change during the disease course, owing to secondary
rearrangement processes mediated via ongoing activity of the
V(D)J recombinase enzyme system (reviewed by Szczepan´ski et
al12). This might lead to loss of the PCR target and consequently to
false-negative MRD results. Such changes were most frequently
described for Ig heavy chain genes (IGH) and to lesser extent for
TCR genes and were found particularly in cases of precursor-B–
ALL that already contained subclones at diagnosis.13-18
Although the presence of clonal evolution phenomena is widely
acknowledged, its actual impact on the effectiveness of MRD
monitoring has not been defined. So far, studies assessing the
stability of Ig and TCR gene rearrangements at diagnosis and
relapse of ALL either did not compare junctional region sequences
or were limited to particular gene loci.13-18 Therefore, we studied
the stability of the currently used Ig/TCR rearrangements (IGH,
Igk light chain [IGK], TCRg [TCRG], and TCRd [TCRD] gene
rearrangements) in a large series of 96 childhood precursor-B–ALL
patients. This information is essential for reliable selection of
MRD-PCR targets with minimal chance of false-negative results.
Patients, materials, and methods
Patients
Bone marrow or peripheral blood samples from 96 childhood precursor-B–
ALL patients were obtained at initial diagnosis and at relapse (91 patients)
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or at presumably secondary acute myeloid leukemia (AML) (5 patients).
The age distribution ranged from 1 month to 183 months. Eight children
(8%) were infants (age , 1 year). The diagnosis of precursor-B–ALL was
made according to French-American-British and standard immunopheno-
typic criteria.19-21 Immunologic marker analysis of the precursor-B–ALL
revealed that 6 (6%) were pro-B–ALL, 59 (61%) were common ALL, and
31 (32%) were pre-B–ALL. Seven patients were studied at 2 subsequent
leukemia relapses. Cell samples of 52 patients were obtained from the cell
bank of the Dutch Childhood Leukemia Study Group.
Comparative immunophenotypic analysis revealed intralineage switches
in 21% (18 of 86) of precursor-B–ALL patients with available detailed
immunophenotypic data at relapse, which is slightly higher than reported
previously.22
The rationale, methodology, and pitfalls of the stepwise molecular
comparison of the Ig/TCR gene rearrangements between diagnosis and
relapse of precursor-B–ALL were previously exemplified in the case report
of patient 5498, also included in these series.23 A small subgroup of patients
(n 5 21) was studied before by comparative Southern blotting and PCR
analysis of k-deleting element (Kde) rearrangements at diagnosis
and relapse.24
Comparative Southern blot analysis
Mononuclear cells were separated from bone marrow or peripheral blood
samples by Ficoll-Paque centrifugation (density 1.077 g/cm3; Pharmacia,
Uppsala, Sweden). DNA was isolated from frozen mononuclear cells,
digested with the BglII enzyme, and blotted to nylon membranes as
described previously.25 IGH and IGK gene configurations were analyzed
with the IGHJ6, IGKJ5, IGKC, and IGKDE probes (DAKO, Carpinteria,
CA).26,27 The configuration of the TCRD genes was analyzed with the
TCRDJ1 probe (DAKO).28 The diagnosis and relapse samples of the 96
patients were always run in parallel lanes (Figure 1), except for 6 patients
who were exclusively analyzed at diagnosis because of insufficient amounts
of DNA from relapse samples. The Southern blot configuration of the Ig
and/or TCR genes in 73 patients at diagnosis and in 30 patients at relapse
has been reported previously.6,15
PCR amplification and comparative heteroduplex
analysis of PCR products
Independent of Southern blotting, PCR analysis could be performed on both
diagnosis and relapse samples in 89 patients, essentially as described
previously.7,29 Four patients with a secondary AML and 3 precursor-B–ALL
patients with insufficient remaining DNA at diagnosis were not analyzed. In
each 50 mL PCR reaction, 50 ng DNA sample, 6.3 pM of the 59 and 39
oligonucleotide primers, and 0.5 U AmpliTaq Gold polymerase (PE
Biosystems, Foster City, CA) were used. The sequences of the 25
oligonucleotide primer pairs used for amplification of IGH (5 VH family–
specific framework 1 primers and 7 DH family–specific primers with
consensus JH primer), IGK-Kde (4 Vk family–specific primers and intron
recombination signal sequence [RSS] primer with Kde primer), TCRG (6
Vg-Jg primer combinations most frequently used in precursor-B–ALL),
and TCRD gene rearrangements (Vd2-Dd3 and Dd2-Dd3 primer pairs)
were previously published.7,30,31 PCR conditions were as follows: initial
denaturation for 10 minutes at 94°C, followed by 40 cycles of 45 seconds at
92°C, 90 seconds at 60°C, and 2 minutes at 72°C using a Perkin-Elmer 480
thermal cycler (PE Biosystems). After the last cycle an additional extension
step of 10 minutes at 72°C was performed. Appropriate positive and
negative controls were included in all experiments.7
For heteroduplex analysis, the PCR products were denatured at 94°C for
5 minutes after the final cycle of amplification and subsequently cooled to
4°C for 60 minutes to induce duplex formation.32 Afterward the duplexes
were immediately loaded on 6% nondenaturing polyacrylamide gels in
0.5 3 Tris-borate-EDTA buffer, run at room temperature, and visualized by
ethidium bromide staining.32
Relapse samples were at first analyzed with those primer combinations,
which showed clonal PCR products at diagnosis. When the clonal PCR
product was also found at relapse, its identity was subsequently compared
with the PCR product found at diagnosis by means of mixed heteroduplex
analysis, ie mixing of the diagnosis and relapse PCR products followed by
heteroduplex analysis (Figure 2).23 When clonal PCR products found at
diagnosis were undetectable at relapse, the relapse sample was then
analyzed with additional primer combinations for the involved gene loci.
Sequence analysis of Ig/TCR gene rearrangements
Clonal PCR products discordant between diagnosis and relapse of precursor-
B–ALL as found by mixed heteroduplex analysis were directly sequenced.
Sequencing was performed using the dye-terminator cycle sequencing kit
with AmpliTaq DNA polymerase FS on an ABI 377 sequencer (PE
Biosystems) as previously described.31 VH, DH, and JH segments were
identified using DNAPLOT software (W. Mu¨ller, H.-H. Althaus, University
of Cologne, Germany) by searching for homology with all known human
germline VH, DH, and JH sequences obtained from the VBASE directory
of human Ig genes (http://www.mrc-cpe.cam.ac.uk/imt-doc/).33 Vg and Jg
gene segments were identified by comparison to germline TCRG sequences
as previously described.34
Statistical analysis
Statistical analysis using the x2 test on a 2 3 2 table was performed to
compare the frequencies of particular Ig/TCR gene rearrangements between
different precursor-B–ALL patient subgroups. Pearson correlation coeffi-
cient was calculated to test an association between variables. P values less
than or equal to .05 were considered statistically significant.
Results
Southern blot configuration of Ig and TCR genes
in relapsed ALL patients
The configuration of IGH, IGK, and TCRD genes was established
with multiple Southern blot probes. This concerned all 96 patients
Figure 1. Comparative Southern blot analysis of IGH gene configuration in 6
precursor-B–ALL patients. Monoclonal patients 5438 and 5260 (patient with
trisomy 14) show identical gene rearrangements at diagnosis and at relapse. In
monoclonal patient 5117, one allele at relapse is deleted and another one is
preserved. Patient 5257 demonstrates biallelic IGH deletion at both disease stages.
Oligoclonal patient 4910 and monoclonal patient 5282 (the upper weak band in the
diagnosis lane is derived from previous hybridization) show completely changed IGH
gene rearrangement patterns. While sequence analysis has proven a clonal relation-
ship between diagnosis and relapse in patient 4910, patient 5282 most likely
represents a secondary ALL.
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at diagnosis of precursor-B–ALL and 91 patients at subsequent
relapse or secondary AML (Figure 1). This gave us the unique
opportunity to address the question of whether there are any
differences in Ig/TCR gene configuration between the patients who
relapsed compared with the total childhood precursor-B–ALL
group. This comparison is summarized in Table 1, which shows
that the Ig/TCR gene rearrangement patterns at diagnosis and at
relapse in patients included in this study are largely comparable to
each other and to previously published data derived from large
series of random childhood precursor-B–ALL cases at initial
diagnosis.6,27 Only 2 immunogenotypic features were more preva-
lent in ALL at relapse. The TCRD gene configuration at relapse was
characterized by significantly less frequent Vd2-Dd3 and Dd2-Dd3
rearrangements and more frequent TCRD deletions (P , .05),
which reflects ongoing deletional rearrangements. Secondly, the
frequency of IGH and TCRD oligoclonality at relapse was slightly
less frequent, but this difference was only significant for TCRD
(P , .05).
The configuration of Ig/TCR genes compared between 2
subsequent relapses in the 7 patients analyzed showed evidence for
clonal evolution in only 2 cases (concerning 1 or 2 gene rearrange-
ments), while in 5 of the 7 cases we observed some changes in gene
rearrangement patterns between diagnosis and first relapse.
Southern blot analysis in 4 of 5 patients with a presumed
secondary AML demonstrated the complete absence of clonal
Ig/TCR gene rearrangements (Figure 3), which is in line with the
AML diagnosis. However, in one patient (3991) 3 clonal Southern
blot bands were preserved in the AML clone, and the sequence
identity was confirmed by comparative PCR analysis for 2 VH-JH
Figure 2. Examples of comparative heteroduplex PCR analysis. (A) Compara-
tive heteroduplex analysis of IGH gene rearrangements. Monoclonal homodu-
plexes (ho) in patients 5766, 6335, and 6124 found at diagnosis and at relapse
were of the same size. Mixing of the PCR products of these disease phases
followed by heteroduplex PCR analysis demonstrated no heteroduplex (he)
formation, proving that these gene rearrangements had identical junctional
regions. In patient 5784, monoclonal homoduplexes found at diagnosis and at
relapse slightly differed in size. Mixing of the VH4-JH PCR products followed by
heteroduplex PCR analysis demonstrated clear heteroduplex formation, proving
that these VH4-JH gene rearrangements had different junctional regions;
(ss) indicates remaining single-strand fragments. (B) Comparative heteroduplex
analysis of Kde rearrangements showed completely identical rearrangements at
diagnosis and at relapse. (C) Comparative heteroduplex analysis of Vd2-Dd3
gene rearrangements. Patients 5373 and 5513 with monoallelic and biallelic
rearrangements, respectively, had stable Vd2-Dd3 rearrangements. In contrast,
Vd2-Dd3 joinings at diagnosis in patients 5171 and 5514 are oligoclonal, while in
both cases 2 monoclonal Vd2-Dd3 rearrangements were found at relapse.
Table 1. Comparison of Ig and TCR gene rearrangement patterns
based on Southern blotting
Random precursor
B–ALL at diagnosis*
Relapsed precursor-
B–ALL at diagnosis†
Precursor-B–ALL at
relapse
IGH
Germline 0 0 0
R/G 1% (1/97) 2% (2/92) 5% (4/85)
R/R 88% (85/97) 88% (81/92) 85% (72/85)
R/D 8% (8/97) 7% (6/92) 7% (6/85)
D/G 2% (2/97) 1% (1/92) 1% (1/85)
D/D 1% (1/97) 1% (1/92) 2% (2/85)
Oligoclonal 36% (35/97) 42% (38/92)‡ 28% (24/85)§
IGK-Kde
Germline 50% (55/111) 51% (47/92) 49% (42/86)
R/G 28% (31/111) 21% (19/92) 23% (20/86)
R/R 23% (25/111) 28% (26/92) 28% (24/86)
Oligoclonal Not determined 3% (3/92) 1% (1/86)
TCRG
Germline 41% (79/192) 38% (35/91) 41% (37/91)
R/G or R/R 59% (113/192) 62% (56/91) 59% (54/91)
TCRD
Germline 11% (22/202) 8% (7/91) 12% (10/85)
R/G 15% (30/202) 11% (10/91) 8% (7/85)
R/R 23% (47/202) 24% (22/91) 12% (10/85)\
R/D 17% (35/202) 20% (18/91) 22% (19/85)
D/G 5% (11/202) 4% (4/91) 5% (4/85)
D/D 28% (57/202) 33% (30/91) 41% (35/85)\
Oligoclonal 21% (13/62) 26% (24/91) 12% (10/85)\
*The frequencies of particular Ig/TCR gene rearrangements in the random
precursor-B–ALL group at diagnosis are derived from our previous studies.6,27,46
†Including one patient with phenotypic switch to AML at relapse.
‡The frequency of IGH oligoclonality was significantly higher in infant ALL
compared with noninfant ALL (75% vs 38%, P , .05).
§Not significant.
\P , .05.
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gene rearrangements. Apparently the original ALL clone under-
went a phenotypic switch to AML. This patient was included in our
further comparative diagnosis-relapse analyses despite the pheno-
typic shift, while the other 4 patients were excluded.
PCR detectability of Ig and TCR gene rearrangements
in relapsed precursor-B–ALL patients
A total of 362 clonal PCR products of different Ig/TCR gene
rearrangements were identified at diagnosis in 87 (98%) of 89
patients, with an average of 4 targets per patient. In one patient no
clonal gene rearrangements were detected by PCR, while Southern
blotting showed a single weak rearranged IGH band, identical
between the diagnosis and relapse sample. The second patient had
an infant ALL and was fully oligoclonal at diagnosis, which
precluded identification of clonal Ig/TCR markers for PCR-based
MRD monitoring. Generally, IGH oligoclonality at diagnosis was
more prevalent in infant ALL patients (6 of 8 cases), compared with
the noninfant precursor-B–ALL cases (32 of 84 cases), P , .05.
Stability of particular MRD-PCR targets in monoclonal and
oligoclonal precursor-B–ALL patients at relapse
A total of 256 (71%) of 362 clonal Ig/TCR gene rearrangements
identified with heteroduplex PCR analysis at diagnosis in 87
patients were preserved at relapse. This concerned 99 (64%) of 155
IGH, 54 (90%) of 60 IGK-Kde, 65 (75%) of 87 TCRG, and 38
(63%) of 60 TCRD gene rearrangements (Table 2). In 3 additional
patients, Southern blot analysis provided conclusive information
about stability of gene rearrangement patterns.6,15
In 36 patients (including patient 4616 studied exclusively by
Southern blotting) all MRD-PCR targets identified at diagnosis
were preserved at relapse (Figure 4A). In 38 cases (including
patients 2665 and 4501 studied exclusively by Southern blotting) at
least half of the targets remained stable during the disease course
(Figure 4B). In another 10 patients (including patient 3991 with
AML at relapse; Figure 3) most MRD-PCR targets were absent at
relapse but at least one rearrangement was common for both
diagnosis and relapse samples (Figure 4C). Consequently, at least
one MRD-PCR target was preserved at relapse in 84 (93%) of 90
patients with available clonal MRD-PCR targets at diagnosis. In
the remaining 6 patients all clonal markers found at diagnosis
seemed to be lost. However, in 3 of these 6 cases the clonal
Figure 3. Ig/TCR gene rearrangement stability in 5 precursor-B–ALL patients
subjected to comparative heteroduplex PCR analysis at diagnosis and at
presumably secondary AML. All Ig/TCR gene rearrangements identified at diagno-
sis in patients 3797, 4522, 5407, and 5985 were lost, which is in line with secondary
AML. In contrast, several IGH and IGK gene rearrangements in patient 3991 were
preserved, suggesting a phenotypic shift from ALL to AML. Black squares represent
monoclonal rearrangements; gray squares, biclonal/oligoclonal rearrangements;
white squares, oligoclonal/polyclonal rearrangements. All squares above the line
represent stable MRD-PCR targets, while all squares below the line represent Ig/TCR
gene rearrangements lost owing to clonal evolution. VH indicates VH-JH gene
rearrangements; DH, DH-JH gene rearrangements; Vk, Vk-Jk gene rearrangements;
Vg, Vg-Jg gene rearrangements; Jd, rearrangements to Jd1-Dd3 region detected by
Southern blot analysis.
Table 2. Stability of MRD-PCR targets in patients with monoclonal and oligoclonal Ig and TCR gene configuration
Stability of MRD-PCR targets Stability in patients (all l $ 1)
Monoclonal Oligoclonal Total Monoclonal Oligoclonal Total
IGH
VH-JH 88% 47% 69% 81%/98% 37%/73% 63%/88%
(n 5 67) (n 5 60) (n 5 127)
DH-JH 57% 38% 43% 67%/67% 27%/53% 33%/57%
(n 5 7) (n 5 21) (n 5 28)
All 85% 44% 64% 76%/98% 24%/76% 52%/88%
(n 5 74) (n 5 81) (n 5 155) (n 5 42) (n 5 33) (n 5 75)
IGK-Kde
Vk-Kde 95% 40% 91% 94%/97% 33%/66% 88%/94%
(n 5 39) (n 5 5) (n 5 44)
Intron-Kde 86% 0% 87% 92%/92% 0% 85%/85%
(n 5 15) (n 5 15)
All* 95% 40% 90% 95%/95% 33%/66% 88%/93%
(n 5 55) (n 5 5) (n 5 60) (n 5 37) (n 5 3) (n 5 40)
TCRG
Vg-Jg ND ND 75% ND ND 64%/83%
(n 5 87) (n 5 53)
TCRD
Dd2-Dd3 100% 14% 63% 100% 14%/14% 60%/60%
(n 5 9) (n 5 7) (n 5 16)
Vd2-Dd3 81% 31% 63% 75%/80% 20%/50% 59%/71%
(n 5 27) (n 5 16) (n 5 43)
All† 86% 26% 63% 80%/88% 14%/36% 56%/69%
(n 5 37) (n 5 23) (n 5 60) (n 5 25) (n 5 14) (n 5 39)
ND indicates not done.
*Including one Vk-intronRSS rearrangement.
†Including one Vd3-Jd1 rearrangement.
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relationship between diagnosis and relapse was confirmed by the
identification of a common DH-JH stem shared by respective
VH-JH gene rearrangements. In another 2 cases additional analy-
ses35,36 showed at both disease stages identical DNA sequences of
Vk-Jk (5771) and chimeric MLL-AF4 fusion genes (5978), respec-
tively (data not shown). Finally, in one patient (5282) there was no
evidence for a common origin of diagnosis and relapse clones
(Figures 1 and 4C). Because all original monoclonal rearrange-
ments were lost in this case at relapse, we believe that this is in fact
a secondary ALL.
Stability of MRD targets is not related to age, blood cell
counts, or remission duration
Stability of MRD-PCR targets did not significantly correlate with
age or white blood cell count at diagnosis or with remission
duration, ie, time span between diagnosis and relapse.
IGH gene rearrangements
Clonal IGH gene rearrangements were detected by PCR in 75 of
the 90 studied childhood precursor-B–ALL patients. In 66 cases
(88%) at least one IGH MRD-PCR target was preserved at relapse.
In 12 additional patients PCR analysis did not result in identifica-
tion of clonal IGH rearrangements, while Southern blot data
suggested the preservation of at least one target in all 12 patients
(fully identical IGH configuration in 9 cases). In 3 patients
deletions of JH region were identified by Southern blotting both at
diagnosis and at relapse of ALL. The Southern blot results of these
15 patients were not used for calculating the stability of the IGH
PCR targets.
The stability of the IGH PCR targets was markedly different
between oligoclonal and monoclonal patients, ie, at least one
MRD-PCR target was preserved in 76% and 98% of patients,
respectively (Table 2). This significant difference was even more
pronounced at the MRD-PCR target level, with 63 (85%) of 74
monoclonal IGH gene rearrangements being stable compared with
only 36 (44%) of 85 oligoclonal rearrangements. Taking into
account the type of IGH gene rearrangement, complete VH-JH
recombinations were characterized by a higher stability compared
with incomplete DH-JH rearrangements, with 69% versus 43% of
targets preserved, respectively.
Figure 4. Ig/TCR gene rearrangement stability patterns in 87 precursor-B–ALL patients subjected to comparative heteroduplex PCR analysis at diagnosis and at
relapse. Black squares represent monoclonal rearrangements; gray squares, biclonal/oligoclonal rearrangements; white squares, oligoclonal/polyclonal rearrangements
detectable as weak Southern blot bands. All squares above the upper line represent stable MRD-PCR targets, while all squares below the lower line represent Ig/TCR gene
rearrangements lost owing to clonal evolution. VH squares between the 2 lines have common DH-JH stems shared by different IGH rearrangements at diagnosis and at
relapse. (A) Thirty-five patients with all PCR-MRD targets identified at diagnosis preserved at relapse; (B) 36 cases with some targets (ranging from one target to half of the
targets) lost during disease course; (C) 16 patients with most or all clonal markers absent at relapse. Patient 4790 was not included in our evaluation of MRD-PCR target
stability because the detected IGH and TCRG gene rearrangements at diagnosis were oligoclonal. VH indicates VH-JH gene rearrangements; DH, DH-JH gene
rearrangements; Vk, Vk-Kde gene rearrangements; ik, intronRSS-Kde gene rearrangements; Vg, Vg-Jg gene rearrangements; Vd, Vd2-Dd3 gene rearrangements; Dd,
Dd2-Dd3 gene rearrangements.
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IGK deletional rearrangements
A total of 60 IGK deletional rearrangements were detected in 40
childhood precursor-B–ALL patients at diagnosis: 44 Vk-Kde,
15 intron-Kde, and 1 rarely occurring Vk-intron RSS recombina-
tion. At least one of the rearrangements was preserved in 37
cases (93%). In fact, IGK-Kde recombinations represented the
most stable MRD-PCR targets, with 90% of all targets pre-
served. Most (55 of 60) Kde rearrangements were monoclonal
and highly stable (52 targets preserved; 95%), while only 2 of 5
oligoclonal IGK-Kde targets were found at relapse. No signifi-
cant difference in stability was found between Vk-Kde and
intron-Kde rearrangements.
TCRG gene rearrangements
A total of 87 TCRG gene rearrangements were detected in 53
precursor-B–ALL patients at diagnosis, and in 44 cases (83%) at
least one MRD-PCR target was preserved at relapse. Because
accurate oligoclonality detection in TCRG locus is rather complex,
even by Southern blotting,37 we did not evaluate whether there
were any differences in MRD-PCR target stability between mono-
clonal and oligoclonal patients.
TCRD gene rearrangements
A total of 60 clonal TCRD gene rearrangements (43 Vd2-Dd3, 16
Dd2-Dd3, and 1 Vd3-Jd1) were identified by PCR in 39 precursor-
B–ALL patients. At least one of the clonal rearrangements was
preserved in 27 (69%) of 39 cases. Once again we observed striking
differences in stability between monoclonal and oligoclonal pa-
tients, ie, at least one target was preserved in 88% and 36% of
patients, respectively (Table 2). Only 26% of oligoclonal targets
were preserved compared with 86% of monoclonal targets. More-
over, in 10 patients Southern blot data suggested the presence of a
clonally rearranged band corresponding to Vd2-Dd3 rearrange-
ments, while heteroduplex PCR analysis of these rearrangements
showed oligoclonality or even polyclonality.6
Patterns of clonal evolution in precursor-B–ALL patients
with unstable targets
Based on combined Southern blot, PCR, and sequence analysis, it
was possible to follow the patterns of clonal evolution leading to
disappearance of rearrangements that were originally present
at diagnosis.
Clonal evolution in the IGH locus
Owing to clonal evolution phenomena, 62 IGH targets in 36
patients were lost. We could determine the exact patterns of clonal
evolution in 8 patients with monoclonal IGH gene rearrangements
and in 26 patients with an oligoclonal rearrangement pattern.
In 7 patients (2 monoclonal and 5 oligoclonal) Southern blot
rearrangement patterns between diagnosis and relapse were identi-
cal, while PCR analyses showed disappearance of a single rearrange-
ment. This might be explained by the disappearance of minor
subclones undetectable by Southern blotting. In 3 patients with
monoclonal IGH configuration, one of the rearrangements was
changed both in Southern blotting and PCR, while sequence
comparison showed VH replacement with a preserved VH-N-DH-
N-JH junction. In another 2 monoclonal patients we observed
clonal “regression” of one of the rearrangements to germline.
Finally, in a single patient (5282) both monoclonal IGH rearrange-
ments were replaced by 2 new unrelated rearrangements; this
patient was suspected of having developed a secondary ALL
(Figure 4C).
In 11 oligoclonal patients, the IGH configuration at relapse was
monoclonal, which is suggestive of clonal selection during the
treatment. In another 10 oligoclonal patients, IGH was also
oligoclonal at relapse, with several rearrangements lost and with
emergence of new (sub)clones. Sequence comparison was fully
completed in 12 oligoclonal patients with changes at relapse,
indicating ongoing VH to DH-JH joinings with preservation of
common DH-JH stems in 5 patients and possibly secondary
rearrangements in 5 other cases. In the remaining 2 oligoclonal
patients, the IGH sequences were unrelated and suggestive of the
development of diagnosis and relapse clones from a common
clonal progenitor via independent secondary rearrangements.
Clonal evolution in the TCRG locus
Clonal evolution of TCRG gene rearrangements was observed in 19
patients, leading to loss of 22 MRD-PCR targets. In 9 patients this
concerned “regression” of clonal rearrangements most probably to
germline configuration. In 5 patients the new rearrangements at
relapse contained upstream Vg and downstream Jg segments as
compared with the Vg-Jg rearrangements at diagnosis, which is
suggestive of ongoing recombination with Vg-Jg replacement. In
the remaining 5 patients the sequence comparison of Vg-Jg
rearrangements at diagnosis and at relapse excluded secondary
rearrangements and indicated the emergence of a clone related to
the initial (pre)leukemic clone but different from the predominant
clone at diagnosis.
Clonal evolution in the TCRD locus
Clonal evolution in the TCRD locus resulted in the loss of 22
MRD-PCR targets in 17 patients (5 monoclonal and 12 oligoclonal
cases). In 6 patients (including 4 patients with monoclonal
Vd2-Dd3 rearrangements) ongoing deletions were observed. In
contrast, in 8 patients (including 1 patient with monoclonal
Vd2-Dd3) the rearrangement pattern “regressed” to germline
configuration. Finally, in the remaining 3 cases new rearrange-
ments were found at relapse, including 1 Vd2-Dd3 joining and 2
unidentified rearrangements to the Dd3-Jd1 region. Interestingly, 5
of 10 cases with oligoclonal/polyclonal Vd2-Dd3 rearrangements
at diagnosis had a monoclonal TCRD configuration at relapse with
a single Vd2-Dd3 joining. In the remaining 5 patients, ongoing
TCRD deletion was assumed in 2 cases, 2 patients demonstrated
“regression” to germline configuration, and only a single patient
preserved the oligo/polyclonal Vd2-Dd3 rearrangement pattern
at relapse.
Discussion
Our comparative Southern blot, PCR, and sequencing analyses of
childhood precursor-B–ALL at diagnosis and relapse have pro-
vided detailed insight in the stability and changes of Ig and TCR
gene rearrangements during the disease course. This information is
essential for reliable application of Ig/TCR gene rearrangements as
MRD-PCR targets in childhood ALL. However, one should be
cautious with extrapolating these data to adolescent or adult
precursor-B–ALL patients, because the immunogenotype of adult
precursor-B–ALL has more immature features.29
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The Ig/TCR gene rearrangement patterns at diagnosis in
relapsed patients appeared to be comparable to those in a random
series of newly diagnosed pediatric precursor-B–ALL, implying
that the various Ig/TCR gene characteristics at diagnosis have no
prognostic value. This is in contrast to the previously reported
strong predictive value of the Vd2-Dd3 gene rearrangement or the
overall clonal diversity.38,39 The overall Ig/TCR gene configuration
patterns at relapse were largely comparable to those at diagnosis
but were characterized by less oligoclonality and more frequent
TCRD gene deletions. These 2 differences fit with the concept of
ongoing clonal selection and continuing rearrangements.
The detailed molecular analyses proved the clonal relationship
between diagnosis and relapse in 88 of 89 childhood precursor-B–
ALL with identified MRD-PCR markers at diagnosis. In only one
patient (5282) were the Ig/TCR gene rearrangement patterns at
diagnosis and relapse completely different with unrelated junc-
tional region sequences (Figures 1 and 4C). Consequently, the
presumed ALL relapse in this child (3.5 years after diagnosis)
might in fact represent a secondary leukemia. This single patient
confirms previous observations that ALL rarely occurs as second
malignancy after previous cytotoxic treatment.40 This is in contrast
to secondary AML, which affects approximately 4% of children
treated for ALL with cytotoxic regimens containing topoisomerase
II inhibitors.41 We indeed proved the presence of secondary AML
with germline Ig/TCR genes in 4 (4%) of the 96 patients (Figure 3).
However, in a fifth patient we demonstrated the clonal relationship
between the precursor-B–ALL at diagnosis and the presumed
secondary AML, which in fact represented a phenotypic switch.
The comparison of Ig/TCR gene rearrangement patterns be-
tween diagnosis and relapse showed marked heterogeneity in the
occurrence of clonal evolution phenomena. In 40% of patients all
PCR-identified clonal Ig/TCR rearrangements were present at
relapse (Figure 4A), and in another 42% of cases at least half of the
identified gene rearrangements remained stable at relapse (Figure
4B). Extreme clonal evolution with differential outgrowth of
subclones characterized the remaining 18% of cases (Figure 4C), in
whom most or even all clonal Ig/TCR gene rearrangements
identified at diagnosis were lost during disease course. Interest-
ingly, in contrast to the frequent occurrence of clonal evolution
between diagnosis and relapse, we did not observe major clonal
instability of Ig/TCR genes between 2 consecutive relapses (7
cases), which is in line with previous observations.14
Previous studies suggested that the risk of changes in Ig/TCR
rearrangement patterns increases with time.15,42 We did not find a
significant correlation between remission duration and target
stability in this extensive study. This is in line with the report that
clonal selection processes can already occur in early treatment
phases and the reports on clonal identity between diagnosis and
very late relapse of precursor-B–ALL.43-45
In this extensive molecular study, we wished to identify the
factors associated with the occurrence of clonal evolution and
therefore the increased risk of false-negative MRD-PCR results. It
is entirely clear from our study that discrimination between
monoclonality versus oligoclonality at diagnosis is the most
powerful predictor of clonal evolution during the ALL disease
course. All other variables, such as age, white blood cell count, and
immunophenotype at diagnosis, failed to identify patients prone to
clonal evolution of their Ig/TCR gene rearrangements. Monoclonal
MRD-PCR targets were characterized by high stability, with 89%
of all targets detectable at relapse. In contrast, only 40% of the
oligoclonal MRD-PCR targets were preserved at relapse. There-
fore, it is probably important to discriminate between monoclonal
and oligoclonal Ig/TCR rearrangements, which requires a com-
bined Southern blot and PCR approach. Southern blotting is
particularly informative for detection of oligoclonality in IGH and
IGK gene rearrangements, whereas heteroduplex PCR analysis in
combination with Southern blotting is informative for detection of
oligoclonal TCRD gene rearrangements. Southern blotting needs
more DNA and is more labor intensive and time consuming than
PCR techniques. However, with a single BglII restriction enzyme
digestion it is possible to detect oligoclonality in IGH, IGK, and
TCRD loci.26-28 Judging clonality solely from the number of PCR
products per gene would result in marked underestimation of
oligoclonality; eg, at least one third of the oligoclonal IGH targets
(29 of 85, including 15 lost MRD-PCR markers) would have been
classified as monoclonal.
The herein presented detailed comparison of Ig/TCR gene
rearrangement patterns provides important information for appro-
priate selection of PCR targets for MRD monitoring. It is already
accepted that preferably 2 MRD-PCR targets should be used per
patient. Furthermore, our data show that monoclonal targets should
be chosen as first option. As previously suggested, monoclonal Kde
rearrangements were characterized by the best stability (95%),
owing to their end-stage character.24,30 In addition, approximately
85% of monoclonal IGH and TCRD gene rearrangements remained
stable at relapse (Table 2). In monoclonal VH-JH rearrangements,
it is particularly attractive to position the patient-specific primers/
probes at the VH-DH part of the junctional region, which is a
preferred strategy in current RQ-PCR based strategies.9-11 Identifi-
cation of preferably 2 monoclonal MRD-PCR targets (IGH, IGK,
and/or TCRD) was possible in 67 (77%) of 87 patients. When
applying these monoclonal targets, the detection of relapse would
have been possible in 65 patients, but false-negative results would
have been obtained in 2 patients: one with presumably secondary
Figure 5. Flow diagram. Flow diagram for the stepwise selection of MRD-PCR
targets, dependent on the choice of techniques for detection and identification of IGH,
IGK, TCRD, and TCRG gene rearrangements.
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ALL and an infant case characterized by extensive clonal Ig/TCR
evolution. The second choice for target selection should concern
oligoclonal IGH gene rearrangements. Although these rearrange-
ments are particularly prone to ongoing and secondary recombina-
tion processes, they are the sole MRD-PCR targets in approxi-
mately 10% of childhood precursor-B–ALL patients.46 In the case
of oligoclonal IGH targets, the patient-specific primers/probes
should preferably be positioned at the D-N-J junctions. Moreover,
all identified clonal DH-JH stems should be followed because
restriction to 2 targets would increase the risk of false-negative
MRD results. In our series this approach could have been used in an
additional 17 (20%) of 87 patients with available MRD-PCR
targets and should have resulted in detection of relapse in 15 cases
(false negativity in patients 2308 and 5978 with secondary IGH
gene rearrangements). Finally, successful MRD detection in the
remaining 3 patients could have been accomplished by usage of
TCRG gene rearrangements, which were sole MRD-PCR targets in
these patients. One could argue for the preferred usage of TCRG
gene rearrangements instead of oligoclonal IGH targets. However,
in at least 2 of our patients (4910, 5661) usage of common DH-JH
stems would have been superior to Vg-Jg targets (Figure 4C). More
importantly, TCRG gene rearrangements are generally less sensi-
tive markers in RQ-PCR analyses, owing to their limited combina-
torial diversity and the abundance of polyclonal Vg-Jg joinings in
normal T-cells in postinduction follow-up samples.47 Finally, our
study clearly shows that oligoclonal Vd2-Dd3 and Dd2-Dd3
rearrangements should not be used as MRD-PCR targets, because
most of them (about 75%) would be modified through clonal
evolution processes. The Southern blot and PCR-based strategy for
MRD-PCR target selection (priority order: 2 monoclonal IGH,
IGK, and/or TCRD targets, followed by DH-JH stems of oligo-
clonal IGH rearrangements, followed by TCRG targets with full
exclusion of oligoclonal IGK and TCRD targets) would enable
successful detection of relapse in 83 (95%) of 87 patients with the
currently available MRD-PCR targets (Figure 5).
The above-presented strategy is based on combined Southern
blot and PCR analyses for discrimination between monoclonal and
oligoclonal Ig/TCR gene configuration. However, many MRD-
PCR laboratories do not routinely perform Southern blotting,
implying that they will underestimate the occurrence of oligoclonal-
ity in IGH (44% of patients in this series), TCRD (36%), and IGK
(8%) genes. In an exclusively PCR-based strategy for MRD target
selection, Kde rearrangements should be chosen as first option.
When applying all available Kde targets, the detection of relapse
would have been possible in 37 patients in our series (43%), but
false-negative results would have been obtained in 2 patients. The
second choice for target selection should concern IGH gene
rearrangements. Using all identified IGH gene rearrangements with
patient-specific oligonucleotides positioned at the DH-JH stems
should have resulted in detection of relapse in 43 cases (49%), with
false-negative results in 2 patients. If the design of DH-JH
oligonucleotides is not successful, one might decide to design
VH-DH-JH oligonucleotides supplemented with the usage of
PCR-based monoclonal TCRD targets. Finally, successful MRD
detection in the remaining 3 patients could have been accomplished
by usage of TCRG gene rearrangements (Figure 5). Similarly to the
combined Southern blot/PCR–based approach, the exclusively
PCR-based approach would enable successful detection of relapse
in 95% of patients. Thus, the lack of Southern blot information for
discrimination between monoclonal and oligoclonal PCR targets
might be compensated by monitoring of a higher number of IGH
and TCRD targets (Figure 5).
Both described strategies for selection of MRD-PCR targets
have their advantages and limitations, which should be carefully
weighed in the context of the facilities and experience of each
MRD-PCR laboratory. Nevertheless, each strategy would enable
successful detection of relapse in 95% of patients. If one assumes
that the actual relapse rate in childhood precursor-B–ALL is 25% to
30%, the current Ig/TCR-based MRD-PCR methodology should be
“effective” in 97% to 98% of cases with identifiable MRD-PCR
targets at diagnosis.
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